title: Anabolic effect of human growth hormone: management of inherited disorders of catabolic pathways.
abstract: The effects of growth hormone treatment and dietary alanine supplementation, individually and in combination, were studied in five patients with organic acidemias. Three patients had propionic acidemia, one had 3-hydroxyisobutyric acidemia, and one had a defect in isoleucine metabolism. Two patients with propionic acidemia had decreased growth hormone secretion in response to provocative stimuli (intravenous L-arginine and oral levodopa or clonidine); the remaining subjects had sufficient growth hormone secretion. Three of four subjects in whom IGF1 was measured showed subnormal concentrations at baseline (including two with normal growth hormone secretory responses). All patients showed an increase in linear growth with growth hormone. In the four patients studied, all had a significant increase in nitrogen retention over baseline with alanine or growth hormone alone, or with the combination of growth hormone and alanine, with a much greater effect of growth hormone. Lean body mass and body fat composition tended to become normal with treatment. Protein tolerance increased, and when the patients' dietary protein intakes were increased between 20 and 60% they maintained positive nitrogen balance, without a significant increase in metabolite excretion. One patient with propionic acidemia expired during the time of the study, following a course of recurrent pancreatitis and an episode of acute basal ganglia infarction. All of the other subjects showed clinical improvement (decreased incidence of ketoacidotic episodes and decreased frequency of hospital admission and school absence) during treatment, and even the patient who expired remained metabolically stable up to and through the terminal event. We conclude that growth hormone may be of value in the management of patients with organic acidemia.
authors.affiliation: Department of Pediatrics, University of California San Diego, La Jolla 92093.
authors.forename: D
authors.initials: D
authors.lastname: Marsden
authors.forename: B A
authors.initials: BA
authors.lastname: Barshop
authors.forename: S
authors.initials: S
authors.lastname: Capistrano-Estrada
authors.forename: M
authors.initials: M
authors.lastname: Rice
authors.forename: C
authors.initials: C
authors.lastname: Prodanos
authors.forename: D
authors.initials: D
authors.lastname: Sartoris
authors.forename: J
authors.initials: J
authors.lastname: Wolff
authors.forename: K L
authors.initials: KL
authors.lastname: Jones
authors.forename: S
authors.initials: S
authors.lastname: Spector
authors.forename: W L
authors.initials: WL
authors.lastname: Nyhan
mesh_terms: D020155:3-Hydroxybutyric Acid; D000293:Adolescent; D000365:Age Determination by Skeleton; D015519:Bone Density; D002648:Child; D004044:Dietary Proteins / Q000008:administration & dosage; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D006885:Hydroxybutyrates / Q000652:urine; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007532:Isoleucine / Q000378:metabolism; D008661:Metabolism, Inborn Errors / Q000188:drug therapy*; D009584:Nitrogen / Q000378:metabolism; D011422:Propionates / Q000097:blood
chemical_list: D004044:Dietary Proteins; D006885:Hydroxybutyrates; D011422:Propionates; D007532:Isoleucine; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; C029658:propionic acid; D009584:Nitrogen; D020155:3-Hydroxybutyric Acid